OLD National Bancorp IN Grows Holdings in Celgene Co. (CELG)

OLD National Bancorp IN increased its stake in Celgene Co. (NASDAQ:CELG) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,154 shares of the biopharmaceutical company’s stock after purchasing an additional 3,033 shares during the period. OLD National Bancorp IN’s holdings in Celgene were worth $8,917,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CELG. Thompson Davis & CO. Inc. boosted its stake in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI boosted its stake in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the period. Guidant Wealth Advisors purchased a new stake in shares of Celgene during the third quarter valued at approximately $119,000. Motco boosted its stake in shares of Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 159 shares during the period. Finally, Penserra Capital Management LLC purchased a new stake in shares of Celgene during the second quarter valued at approximately $129,000. 79.74% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently commented on CELG. Vetr raised Celgene from a “hold” rating to a “buy” rating and set a $146.58 price target for the company in a research note on Friday, October 6th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $173.00 price target on shares of Celgene in a research note on Thursday, October 5th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $162.00 price target on shares of Celgene in a research note on Tuesday, September 26th. Robert W. Baird reaffirmed a “buy” rating and issued a $162.00 price target on shares of Celgene in a research note on Thursday, September 21st. Finally, Jefferies Group reiterated a “buy” rating and issued a $160.00 price objective on shares of Celgene in a report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have issued a buy rating to the stock. Celgene has an average rating of “Buy” and an average target price of $131.18.

Shares of Celgene Co. (CELG) opened at $104.58 on Friday. The company has a market capitalization of $82,340.00, a price-to-earnings ratio of 24.67, a P/E/G ratio of 0.68 and a beta of 1.77. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $1.58 earnings per share. research analysts predict that Celgene Co. will post 6.68 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “OLD National Bancorp IN Grows Holdings in Celgene Co. (CELG)” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://stocknewstimes.com/2018/01/12/old-national-bancorp-in-acquires-3033-shares-of-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply